XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Cardiology Channel
subscribe to Cardiology newsletter

Latest Research : Cardiology

   DISCUSS   |   EMAIL   |   PRINT
Sildenafil puts a ‘brake’ on chemical stimulation of heart
Oct 27, 2005, 00:21, Reviewed by: Dr.

“Knowing more about the effects of sildenafil on heart function will allow for safer evaluation of its use as a treatment for heart problems. Until now, it was widely thought that drugs like sildenafil had no effects on the human heart and that its only purpose was vasodilation in the penis and the lungs."

 
Sildenafil citrate (Viagra), a drug used to treat erectile dysfunction (ED) in millions of men, reduces the stimulatory effects of hormonal stress on the heart by half, according to results of a new study by researchers at Johns Hopkins.

While sildenafil is more widely known for helping genital blood vessels expand to maintain an erection and, more recently, as a treatment for pulmonary hypertension, it has been thought to have little direct effect on the human heart.

In the heart, sildenafil blunts the strengthened heartbeat caused by chemically induced stress, thereby lessening the excess amount of blood and force used to pump it to the body, according to study senior author and cardiologist David Kass, M.D., a professor at The Johns Hopkins University School of Medicine and its Heart Institute.

“Sildenafil effectively puts a ‘brake’ on chemical stimulation of the heart,” says Kass.

The researchers’ findings, which appear in the journal Circulation online Oct. 24, are believed to be the first confirmation in humans that sildenafil has a direct effect on the heart. Previous research by Kass and his team showed that sildenafil had such effects in mice, blocking the short-term effects of hormonal stress in the heart. Related studies by the group also showed that sildenafil prevents and reverses the long-term effects in the heart from chronic high blood pressure.

Moreover, Kass adds, the latest Hopkins results confirm that sildenafil helps control heart function only when the heart is under duress, but has little impact under normal conditions.

Separate research from Kass and his team published earlier this year in the journal Nature Medicine showed that, in mice, sildenafil could reverse the negative effects on heart muscle weakened by heart failure and enlargement, a condition called hypertrophy. “But we had no firm evidence as to whether or how this therapy might work in the human heart. Our latest research provides firm evidence this drug does indeed have an important impact on the heart.”

Thirty-five healthy men and women, with an average age of 30 and no previous signs of coronary artery disease, participated in the six-month study. Within a three-hour timeframe, each participant received two separate injections of dobutamine (5 micrograms per kilogram for five minutes), a synthetic, adrenaline-like chemical that increases heart rate and pumping strength.

Between injections, study participants were randomly assigned to a group that was treated with sildenafil (100 milligrams taken orally) or to a group given a sugar pill placebo. All participants were then given the second dobutamine injection to see what effects sildenafil or placebo had on the heart.

Measurements of heart function were made before and after each injection. This included blood pressure readings, electrocardiograms and echocardiograms, as well as blood samples to confirm relatively equal levels of sildenafil and other enzymes.

Results showed that each dobutamine injection stimulated heart function, increasing heart rate and the force of each heartbeat used to pump blood throughout the body.

“This stimulation is similar to the way the nervous system normally increases heart function when triggered by emotional or exercise stress, or in diseases such as heart failure,” adds Kass.

After the first injection of dobutamine, the force of heart contraction increased by 150 percent in both groups. And in the placebo group, this increase repeated itself after the second injection. However, in the group treated with sildenafil, the increased heartbeat was slowed by 50 percent, resulting in a smaller increase in blood flow and blood pressure generated by the heart in response to chemical stimulation.

Between injections, heart function was not altered in the sildenafil group, demonstrating the absence of adverse side effects on the resting human heart.

“Knowing more about the effects of sildenafil on heart function will allow for safer evaluation of its use as a treatment for heart problems,” says Kass. “Until now, it was widely thought that drugs like sildenafil had no effects on the human heart and that its only purpose was vasodilation in the penis and the lungs.

“Our results set the stage for further studies of sildenafil’s immediate and long-term effects on the heart and its ability to modify other neurohormonal and stress stimuli, including adrenaline and hypertension,” he adds.

While the precise biological actions of sildenafil in the heart are not fully understood, the drug is known to work by stopping the action of an enzyme, called phosphodiesterase 5 (PDE5A), the researcher says. This enzyme is involved in the breakdown of a key molecule, cyclic GMP, which helps control stresses and limit overgrowth in the heart. PDE5A is also the biological pathway blocked in the penis by sildenafil to prevent the relaxation of blood vessels and maintain erections.
 

- Journal Circulation, Oct. 24, 2005
 

www.hopkinsmedicine.org

 
Subscribe to Cardiology Newsletter
E-mail Address:

 

Funding for this study was provided by the National Institutes of Health (NIH), the Peter Belfer Laboratory Foundation and the Bernard Family Foundation. The makers of the drug had no involvement in the design or support of the research.

The study, conducted solely at Hopkins, was led by cardiologist Barry Borlaug, M.D. Other researchers involved in this study were Vojtech Melenovsky M.D., Ph.D.; Tricia Marhin, R.N., B.S.N.; and Patricia Fitzgerald, R.N., B.S.N. Kass is also the Abraham and Virginia Weiss Professor of Cardiology at Hopkins.


Related Cardiology News

Seven-point system gauges seriousness of heart failure in elderly
Uric acid levels closely related to hypertension in Blacks
American College of Cardiology announces new initiative to improve safety for patients with Acute Coronary Syndromes
Is TROPHY misleading?
Fortified orange juice decreases not only cholesterol but also CRP
Heart Disease: Blame it on genes!
Famotidine may help to slow progression of chronic heart failure
Atherothrombotic disease is not just a 'western' problem
Changing normal heart cells into pacemakers
Ilk gene underlies heart failure


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us